Title: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Author: Zhu, Dalong, Li, Xiaoying, Ma, Jianhua, Zeng, Jiaoe, Gan, Shenglian, Dong, Xiaolin, Yang, Jing, Lin, Xiaohong, Cai, Hanqing, Song, Weihong, Li, Xuefeng, Zhang, Keqin, Zhang, Qiu, Lu, Yibing, Bu, Ruifang, Shao, Huige, Wang, Guixia, Yuan, Guoyue, Ran, Xingwu, Liao, Lin, Zhao, Wenjuan, Li, Ping, Sun, Li, Shi, Lixin, Jiang, Zhaoshun, Xue, Yaoming, Jiang, Hongwei, Li, Quanmin, Li, Zongbao, Fu, Maoxiong, Liang, Zerong, Guo, Lian, Liu, Ming, Xu, Chun, Li, Wenhui, Yu, Xuefeng, Qin, Guijun, Yang, Zhou, Su, Benli, Zeng, Longyi, Geng, Houfa, Shi, Yongquan, Zhao, Yu, Zhang, Yi, Yang, Wenying, Chen, Li
Issue&Volume: 2022-05-12
Abstract: Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a glucose-dependent manner, improves glucose-stimulated insulin secretion and demonstrates effects on glycemic control in patients with T2D. We report the findings of a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of dorzagliatin in patients with T2D. Eligible drug-nave patients with T2D (n=463) were randomly assigned to the dorzagliatin or placebo group at a ratio of 2:1 for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin from baseline to week 24. Safety was assessed throughout the trial. At week 24, the least-squares mean change in glycated hemoglobin from baseline (95% confidence interval) was 1.07% (1.19%, 0.95%) in the dorzagliatin group and 0.50% (0.68%, 0.32%) in the placebo group (estimated treatment difference, 0.57%; 95% confidence interval: 0.79%, 0.36%; P<0.001). The incidence of adverse events was similar between the two groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin group. In summary, dorzagliatin improved glycemic control in drug-nave patients with T2D and showed a good tolerability and safety profile.
DOI: 10.1038/s41591-022-01802-6
Source: https://www.nature.com/articles/s41591-022-01802-6
Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：30.641
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex